Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer

A randomized, placebo-controlled trial (Alliance A222001) published in the Journal of Clinical Oncology evaluated oxybutynin, an anticholinergic agent, for the management of hot flashes in prostate cancer patients undergoing androgen-deprivation therapy (ADT). Hot flashes are among the most common and distressing side effects of ADT, significantly affecting quality of life for a large proportion of patients. The trial provides level-one evidence on whether oxybutynin, already used off-label for this indication based on limited prior data, can meaningfully reduce hot flash frequency and severity compared to placebo. These findings are important for clinicians seeking evidence-based supportive care options for men on long-term hormonal therapy. The study addresses a practical unmet need in the day-to-day management of prostate cancer survivors.